A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Peginterferon lambda-1a (Primary)
- Indications Hepatitis D
- Focus Therapeutic Use
- Acronyms LIMT; LIMT HDV
- Sponsors Eiger BioPharmaceuticals
- 24 Jul 2017 Status changed from recruiting to active, no longer recruiting according to an Eiger BioPharmaceuticals media release.
- 31 May 2017 Planned number of patients changed from 30 to 40.
- 31 May 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jun 2018.